Cargando…
Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling
AIMS/HYPOTHESIS: The aim of this study was to leverage human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide (GIP) signalling. METHODS: Data were obtained from summary statistics of large-scale genome-wide association studies. We examined wheth...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563538/ https://www.ncbi.nlm.nih.gov/pubmed/34505161 http://dx.doi.org/10.1007/s00125-021-05564-7 |
_version_ | 1784593424118185984 |
---|---|
author | Karhunen, Ville Daghlas, Iyas Zuber, Verena Vujkovic, Marijana Olsen, Anette K. Knudsen, Lotte Bjerre Haynes, William G. Howson, Joanna M. M. Gill, Dipender |
author_facet | Karhunen, Ville Daghlas, Iyas Zuber, Verena Vujkovic, Marijana Olsen, Anette K. Knudsen, Lotte Bjerre Haynes, William G. Howson, Joanna M. M. Gill, Dipender |
author_sort | Karhunen, Ville |
collection | PubMed |
description | AIMS/HYPOTHESIS: The aim of this study was to leverage human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide (GIP) signalling. METHODS: Data were obtained from summary statistics of large-scale genome-wide association studies. We examined whether genetic associations for type 2 diabetes liability in the GIP and GIPR genes co-localised with genetic associations for 11 cardiometabolic outcomes. For those outcomes that showed evidence of co-localisation (posterior probability >0.8), we performed Mendelian randomisation analyses to estimate the association of genetically proxied GIP signalling with risk of cardiometabolic outcomes, and to test whether this exceeded the estimate observed when considering type 2 diabetes liability variants from other regions of the genome. RESULTS: Evidence of co-localisation with genetic associations of type 2 diabetes liability at both the GIP and GIPR genes was observed for five outcomes. Mendelian randomisation analyses provided evidence for associations of lower genetically proxied type 2 diabetes liability at the GIP and GIPR genes with lower BMI (estimate in SD units −0.16, 95% CI −0.30, −0.02), C-reactive protein (−0.13, 95% CI −0.19, −0.08) and triacylglycerol levels (−0.17, 95% CI −0.22, −0.12), and higher HDL-cholesterol levels (0.19, 95% CI 0.14, 0.25). For all of these outcomes, the estimates were greater in magnitude than those observed when considering type 2 diabetes liability variants from other regions of the genome. CONCLUSIONS/INTERPRETATION: This study provides genetic evidence to support a beneficial role of sustained GIP signalling on cardiometabolic health greater than that expected from improved glycaemic control alone. Further clinical investigation is warranted. DATA AVAILABILITY: All data used in this study are publicly available. The scripts for the analysis are available at: https://github.com/vkarhune/GeneticallyProxiedGIP. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains peer-reviewed but unedited supplementary material available at 10.1007/s00125-021-05564-7. |
format | Online Article Text |
id | pubmed-8563538 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-85635382021-11-04 Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling Karhunen, Ville Daghlas, Iyas Zuber, Verena Vujkovic, Marijana Olsen, Anette K. Knudsen, Lotte Bjerre Haynes, William G. Howson, Joanna M. M. Gill, Dipender Diabetologia Short Communication AIMS/HYPOTHESIS: The aim of this study was to leverage human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide (GIP) signalling. METHODS: Data were obtained from summary statistics of large-scale genome-wide association studies. We examined whether genetic associations for type 2 diabetes liability in the GIP and GIPR genes co-localised with genetic associations for 11 cardiometabolic outcomes. For those outcomes that showed evidence of co-localisation (posterior probability >0.8), we performed Mendelian randomisation analyses to estimate the association of genetically proxied GIP signalling with risk of cardiometabolic outcomes, and to test whether this exceeded the estimate observed when considering type 2 diabetes liability variants from other regions of the genome. RESULTS: Evidence of co-localisation with genetic associations of type 2 diabetes liability at both the GIP and GIPR genes was observed for five outcomes. Mendelian randomisation analyses provided evidence for associations of lower genetically proxied type 2 diabetes liability at the GIP and GIPR genes with lower BMI (estimate in SD units −0.16, 95% CI −0.30, −0.02), C-reactive protein (−0.13, 95% CI −0.19, −0.08) and triacylglycerol levels (−0.17, 95% CI −0.22, −0.12), and higher HDL-cholesterol levels (0.19, 95% CI 0.14, 0.25). For all of these outcomes, the estimates were greater in magnitude than those observed when considering type 2 diabetes liability variants from other regions of the genome. CONCLUSIONS/INTERPRETATION: This study provides genetic evidence to support a beneficial role of sustained GIP signalling on cardiometabolic health greater than that expected from improved glycaemic control alone. Further clinical investigation is warranted. DATA AVAILABILITY: All data used in this study are publicly available. The scripts for the analysis are available at: https://github.com/vkarhune/GeneticallyProxiedGIP. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains peer-reviewed but unedited supplementary material available at 10.1007/s00125-021-05564-7. Springer Berlin Heidelberg 2021-09-09 2021 /pmc/articles/PMC8563538/ /pubmed/34505161 http://dx.doi.org/10.1007/s00125-021-05564-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Short Communication Karhunen, Ville Daghlas, Iyas Zuber, Verena Vujkovic, Marijana Olsen, Anette K. Knudsen, Lotte Bjerre Haynes, William G. Howson, Joanna M. M. Gill, Dipender Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling |
title | Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling |
title_full | Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling |
title_fullStr | Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling |
title_full_unstemmed | Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling |
title_short | Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling |
title_sort | leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563538/ https://www.ncbi.nlm.nih.gov/pubmed/34505161 http://dx.doi.org/10.1007/s00125-021-05564-7 |
work_keys_str_mv | AT karhunenville leveraginghumangeneticdatatoinvestigatethecardiometaboliceffectsofglucosedependentinsulinotropicpolypeptidesignalling AT daghlasiyas leveraginghumangeneticdatatoinvestigatethecardiometaboliceffectsofglucosedependentinsulinotropicpolypeptidesignalling AT zuberverena leveraginghumangeneticdatatoinvestigatethecardiometaboliceffectsofglucosedependentinsulinotropicpolypeptidesignalling AT vujkovicmarijana leveraginghumangeneticdatatoinvestigatethecardiometaboliceffectsofglucosedependentinsulinotropicpolypeptidesignalling AT olsenanettek leveraginghumangeneticdatatoinvestigatethecardiometaboliceffectsofglucosedependentinsulinotropicpolypeptidesignalling AT knudsenlottebjerre leveraginghumangeneticdatatoinvestigatethecardiometaboliceffectsofglucosedependentinsulinotropicpolypeptidesignalling AT hayneswilliamg leveraginghumangeneticdatatoinvestigatethecardiometaboliceffectsofglucosedependentinsulinotropicpolypeptidesignalling AT howsonjoannamm leveraginghumangeneticdatatoinvestigatethecardiometaboliceffectsofglucosedependentinsulinotropicpolypeptidesignalling AT gilldipender leveraginghumangeneticdatatoinvestigatethecardiometaboliceffectsofglucosedependentinsulinotropicpolypeptidesignalling |